Differences in the incidence of cirrhosis-associated complications between MASLD, MetALD and ALD among patients with decompensated liver cirrhosis

Ítems similars

• Differences in the incidence of cirrhosis-associated complications between MASLD, MetALD and ALD among patients with decompensated liver cirrhosis
  per: Laura Buttler, et al.
  Publicat: (2025-01-01)
• ACCELERATED PROGRESSION TO CIRRHOSIS AND HEPATIC DECOMPENSATION IN METALD AND ALD COMPARED TO MASLD: A GLOBAL STUDY
  per: Luis Antonio Díaz Piga, et al.
  Publicat: (2025-09-01)
• Effects of renin–angiotensin inhibitors on renal function and the clinical course in patients with decompensated cirrhosis
  per: Tammo L. Tergast, et al.
  Publicat: (2023-10-01)
• Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score
  per: Pimsiri Sripongpun, et al.
  Publicat: (2024-10-01)
• Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents
  per: Guang-Xia Shi, et al.
  Publicat: (2024-10-01)